|
Synonyms: LY 2127399 | LY2127399
Compound class:
Antibody
Comment: Tabalumab is a monoclonal antibody directed against B-cell activating factor (BAFF, TNFSF13B). It was being developed as a treatment for autoimmune diseases [1] and B cell malignancies [2].
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequence BLAST search using the heavy chain variable region of tabalumab provides 100% match to a sequence claimed in patent US7317089 [3], and to the antibody with designation 4A5-3.1.1-B4. |
| Immunopharmacology Comments |
| Tabalumab is a failed Phase 3 anti-BAFF monoclonal antibody. It provided no clinical efficacy in patients with rheumatoid arthritis or SLE. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Rheumatoid arthritis |
Disease Ontology:
DOID:7148 OMIM: 180300 |
Tabalumab was a clinical candidate therapeutic for RA. | |
| Systemic lupus erythematosus |
Disease Ontology:
DOID:9074 OMIM: 152700 Orphanet: ORPHA536 |
Tabalumab was a clinical candidate therapeutic for SLE. | |
